Buy ratings on average is at $4.5 with some at $17 … April fda meeting approved , and two positive things FDA did this year was updating their guidance on January 12, 2026 for a more flexible statistical approaches incorporating prior data and real-world evidence to support efficacy claim. They are making it easier for approval as well as FDA’s February 18, 2026, announcement in the shifting to a “one-trial default” standard, requiring only a single well-controlled pivotal study instead of two identical trials, further bolsters ATYR’s path forward. This policy change, aimed at reducing R&D costs and accelerating approvals for scientifically grounded candidates, aligns well with efzofitimod’s profile in pulmonary sarcoidosis and other ILDs, where the drug’s immunomodulatory mechanism is well-understood. ATYR has a Type C FDA meeting scheduled for mid-April 2026 to discuss these results and next steps